Showing results (121-130 of 6,853) with videos related to

Sort By:
Pageof 686
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]Richard J Willke, Peter J Neumann, Louis P Garrison, et al.
JAMA Otolaryngology-- Head & Neck Surgery|January 31, 2020
Development of a Sleep Apnea-Specific Health State Utility AlgorithmJonathan R Skirko, Kathryn T James, Louis P Garrison, et al.
Journal of Shoulder and Elbow Surgery|March 24, 2024
Patient-reported outcomes following total shoulder arthroplasty and hemiarthroplasty: an analysis of data from the National Joint RegistryAndrew R Davies, Sanjeeve Sabharwal, Alexander D Liddle, et al.
The American Journal of Managed Care|November 1, 2017
What do pharmaceuticals really cost in the long run?Darius Lakdawalla, Joanna P MacEwan, Robert Dubois, et al.
Journal of Cancer Research and Clinical Oncology|May 12, 2009
Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysisJosh John Carlson, Louis P Garrison, Scott D Ramsey, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 14, 2022
Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate CancerBoshen Jiao, Yaw A Nyame, Josh J Carlson, et al.
Journal of Medical Economics|August 14, 2012
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United StatesRoman Casciano, Maruit Chulikavit, Allison Perrin, et al.
Molecular Oncology|March 21, 2012
Paying for personalized care: cancer biomarkers and comparative effectivenessRahber Thariani, David L Veenstra, Josh J Carlson, et al.
Value in Health Regional Issues|February 22, 2023
Estimating the Potential Economic Impact of Tissue Valve Replacement for Heart Valve Disease in China: Patient-Level and Population-Level Cost-Benefit Simulation AnalysesBruce Wang, Elizabeth Wu, Dirk Rassloff, et al.
Applied Health Economics and Health Policy|February 5, 2024
Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice RecommendationsBethany Shinkins, A Joy Allen, James Karichu, et al.
Pageof 686